4Q24 Consolidated Highlights<\/b><\/p>\n FY24 Consolidated Highlights<\/b><\/p>\n Message from Auna\u2019s Executive Chairman and President<\/b><\/p>\n Auna closed the year with another strong quarter, successfully delivering on our full-year 2024 guidance of 20% FXN Adjusted EBITDA growth. Net Income improved to S\/124 million from a loss of S\/214 million in 2023.<\/b><\/p>\n \nThis performance was driven by continued momentum in Mexico, where the AunaWay\u2019s implementation and its patient-centered model continue delivering tangible results, by Peru, our most mature and predictable market that continues to deliver excellent results, and by the resilience of our Colombian operations in the face of ongoing challenges with certain payors.\n<\/p>\n \nWe also strengthened our balance sheet, reducing our Leverage Ratio to 3.56x Net Debt-to-Adjusted EBITDA, marking further progress toward our medium-term target of less than 3.00x. Importantly, we generated positive Adjusted Net Income of S\/146 million for the year.\n<\/p>\n \nOur commitment to advancing healthcare through a value-based care model remains central to our strategy. This approach – integrating data-driven decision-making, physician engagement, and patient-centered care – continues to drive sustainable growth while enhancing medical resolution, optimizing resource utilization, and improving financial performance.\n<\/p>\n \nIn Peru, our fully integrated healthcare and plans business remained strong, as we continue harvesting returns on earlier investments that we made to build, integrate and scale this business. Peru continues to demonstrate the consistent earnings power of Auna\u2019s business model when it is operating at scale.\n<\/p>\n \nIn Mexico, revenue growth and profitability continued to strengthen, as the AunaWay gained additional traction in this key market. Additionally, on March 7th<\/sup> we announced the signing of an exclusive five-year agreement with a physician group practicing at Organizaci\u00f3n Para Cuidado Integral en Oncolog\u00eda, S.A. de C.V., also known as Opci\u00f3n Oncolog\u00eda, the premier oncology ambulatory clinic in Monterrey. This strategic partnership strengthens Auna\u2019s commitment to becoming the leading oncology provider in Mexico and marks a significant step in consolidating oncology services within Auna Mexico.\n<\/p>\n \nIn Colombia, we remain confident in the market\u2019s long-term potential while proactively addressing near-term challenges. Regulatory intervention affecting certain payors, including Nueva EPS, continues to create uncertainty in the sector. In response, we began phasing out select services to Nueva EPS in Antioquia in 1Q25 and adjusting service modalities in other regions, while securing a payment plan for its outstanding balances. Although we have made encouraging progress with Nueva EPS and still expect to recover our receivables, we continue to reallocate service volumes to other payors and diversify our payor mix to strengthen cash flow reliability and operational stability. While this transition may introduce short-term volatility, it ultimately enhances our financial position and flexibility in the country.\n<\/p>\n \nAlso, early this year we welcomed two distinguished C-suite executives from Mexico to our Board of Directors. Their leadership and complementary expertise further enhance Auna\u2019s governance as we scale operations, particularly in Mexico. With these additions, we have increased both independent directors and female representation, reinforcing our commitment to strong decision-making and diversity.\n<\/p>\n \nLooking ahead, we expect continued growth in our markets, focusing on increasing efficiencies across our network and expanding access to high-quality healthcare. We are particularly excited about OncoMexico\u2019s potential with a disruptive product in the country\u2019s insurance market. Auna continues to maintain its internal guideline of 20% FXN Adjusted EBITDA growth annually. In 2025, achieving this goal will depend on the performance of our operations in Colombia. While we have strong momentum across the business, external factors\u2014particularly the challenges posed by the intervened EPSs in Colombia\u2014introduce significant uncertainty. These industry-wide headwinds, rather than any change in our operational performance, will be a key factor in determining the final outcome. We remain focused on executing our AunaWay strategy and are confident in our ability to drive growth and profitability across our markets. We also intend to further reduce debt as we expect to generate additional excess cash flow in 2025.\n<\/p>\n \nAs we enter the new year, Auna is well-positioned to advance our mission and deliver significant value to patients, partners, and shareholders.\n<\/p>\n Overview of 4Q24 and Full-Year 2024 Consolidated Results<\/b><\/p>\n Revenues<\/b> increased 4% YoY to S\/1,063 million, or 11% FXN, as a result of Auna\u2019s improving service mix and pricing across its networks, with revenues in local currency (\u201cL.C.\u201d) increasing 9% in Mexico, 10% in Peru, and 14% in Colombia. FY24 revenues increased 13% YoY, or 12% FXN, with annual L.C. revenues increasing 8% in Mexico, 13% in Peru, and 14% in Colombia.\n<\/p>\n \nIn Mexico, the network improved its services mix and pricing across its three hospitals, similar to the Peruvian healthcare network. In Colombia, risk-sharing models with payors gained traction. In addition, the Oncosalud Peru segment continued expanding its membership base.\n<\/p>\n Adjusted EBITDA<\/b> increased 19% YoY, or 28% FXN, to S\/254 million, with margin expanding 3.1 p.p. to 23.9%, resulting from an operating profit increase of 46% and an expansion in operating margin of 5.1 p.p. to 17.9%. Operating profit included provisions for impairment losses in Colombia of S\/9 million.\n<\/p>\n \nIn FY24, Adjusted EBITDA was S\/993 million, increasing 20% YoY, or 20.1% FXN, in line with Auna\u2019s 2024 annual guidance. Operating profit increased 40% in FY24, representing a 17.9% operating margin, and included: i) a one-time 3Q24 S\/44 million reversal of the holdback from the acquisition of OCA in Mexico, and ii) full-year impairment losses of trade accounts receivable in Colombia of S\/28 million. Consolidated Adjusted EBITDA in FY24 excludes the above-mentioned holdback reversal.\n<\/p>\n Net finance costs <\/b>were S\/155 million in 4Q24 versus S\/302 million in 4Q23. Net interest expenses, excluding FX effects, would have been S\/132 million in 4Q24 and S\/352 million in 4Q23, a decrease of S\/220 million or 63%. 4Q23 included S\/215 million of refinancing costs executed in the quarter related to the exchange of Auna\u2019s 6.500% Senior Notes due 2025 (the \u201c2025 Notes\u201d) and private loan repayments. The FX impact in 4Q24 includes a negative non-cash accounting amount of S\/24 million versus S\/50 million of positive non-cash accounting FX impact in 4Q23, mainly due to the depreciation of the Peruvian Sol against the US Dollar, outside the range of Auna\u2019s call-spread hedge.\n<\/p>\n \nIn FY24, Net finance costs were S\/609 million and included net interest expenses of S\/567 million and a negative non-cash FX effect of S\/42 million, versus net finance costs of S\/691 million in FY23 that included net interest expenses of S\/767 million and a positive non-cash FX effect of S\/76 million due to the appreciation of the Peruvian Sol relative to the US Dollar.\n<\/p>\n Net Income <\/b>was S\/24 million in 4Q24, compared to a Net Loss of S\/219 million in 4Q23. On a per-share basis, Auna reported Net Income of S\/0.30 based on a weighted average number of basic and diluted shares of 74,175,144. In FY24 Net Income was S\/124 million compared to Net Loss of S\/214 million in FY23. On a per-share basis, annual Net Income was S\/1.63 based on a weighted average number of basic and diluted shares of 67,500,074.\n<\/p>\n Adjusted Net Income<\/b> was S\/36 million in 4Q24, versus a loss of S\/6 million in 4Q23. On a per-share basis, Auna reported Adjusted Net Income of S\/0.47 based on a weighted average number of basic and diluted shares of 74,175,144. In FY24 Adjusted Net Income was S\/146 million compared to Adjusted Net Income of S\/14 million in FY23. On a per-share basis, Adjusted Net Income in FY24 was S\/1.97 based on a weighted average number of basic and diluted shares of 67,500,074.\n<\/p>\n \nFor a full version of AUNA\u2019s Fourth Quarter 2024 Earnings Release, please visit: https:\/\/aunainvestors.com\/English\/financial-information\/quarterly-results\/<\/a><\/p>\n Conference Call Details<\/b><\/p>\n When:<\/b> 8:00 a.m. Eastern time, March 11, 2025\n<\/p>\n Who: <\/b>Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.\n<\/p>\n Dial-in:<\/b> +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International) \nTo access Auna\u2032s financial results call via telephone, callers need to press # to be connected to an operator.\n<\/p>\n Webcast:<\/b>click here<\/a><\/p>\n About AUNA<\/b><\/p>\n \nAuna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America\u2032s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31, 2024, Auna\u2019s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,323 beds, and 1.4 million healthcare plans.\n<\/p>\n \nFor more information visit www.aunainvestors.com<\/a><\/p>\n Safe Harbor Statement<\/b><\/p>\n \nThis press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201caim,\u201d \u201destimate,\u201d \u201cintend,\u201d \u201cproject,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cis\/are likely to,\u201d or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, [Net Debt-to-Adjusted EBITDA][Leverage Ratio], 2025 Adjusted EBITDA growth, the expected impact on revenues and profitability of certain initiatives we are pursuing in Mexico, our expected long-term financial position and flexibility as a result of certain initiatives we are pursuing related to payors in Colombia and our target leverage level. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.\n<\/p>\n \nThe forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form F-1 filing with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d).\n<\/p>\n 2025 Financial Guidance Disclaimer<\/b><\/p>\n \nAuna\u2032s guidance is based on management\u2019s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.\n<\/p>\n \nAuna\u2019s 2025 financial guidance reflects management\u2019s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company\u2019s Form F-1 filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically Leverage Ratio guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Leverage Ratio to projected net income without unreasonable effort. The 2025 financial guidance constitutes forward-looking statements. For more information, see the \u201cForward-Looking Statements\u201d section in this release.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250310052802\/en\/<\/a><\/span><\/p>\n\n
\n
\n
Passcode: <\/b>3884034\n<\/p>\n<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250310052802\/en\/2405485\/3\/LOGO_AUNA.jpg\"){kind=logo}
<\/td>\n<\/tr>\n